Literature DB >> 8309563

Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study.

J C Breitner1, B A Gau, K A Welsh, B L Plassman, W M McDonald, M J Helms, J C Anthony.   

Abstract

We conducted a co-twin control study among 50 elderly twin pairs with onsets of Alzheimer's disease (AD) separated by 3 or more years. Twenty-three male pairs (46%) were screened from the (U.S.) National Academy of Sciences-National Research Council Registry (NAS-NRC Registry) of World War II veteran twins; others (mostly women) had responded to advertisements or were referred from AD clinics. Twenty-six pairs (52%) were monozygous. The onset of AD was inversely associated with prior use of corticosteroids or ACTH (odds ratio [OR], 0.25; 95% confidence interval [CI], 0.06 to 0.95; p = 0.04). Similar but weaker trends were present among pairs discordant for history of arthritis or for prior daily use of nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin. The association was strongest when we combined use of steroids/ACTH or NSAIDs post hoc into a single variable of anti-inflammatory drugs (AIs) (OR, 0.24; CI, 0.07 to 0.74; p = 0.01). The inverse relation was strong in female (volunteer) twin pairs but was not present in the younger men from the NAS-NRC Registry. AIs had typically been taken for arthritis or related conditions, but a similar result was apparent after controlling statistically for the arthritis variable (OR, 0.08; CI, 0.01 to 0.69; p = 0.02). AIs have been proposed as a means of retarding the progression of AD symptoms, and these data suggest that AIs may also prevent or delay the initial onset of AD symptoms. Because of limitations in the case-control method, our results require corroboration with hypothesis-driven research designed to control bias and confounding.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8309563     DOI: 10.1212/wnl.44.2.227

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  91 in total

Review 1.  The burden of dementia. A medical and research perspective.

Authors:  P Antuono; J Beyer
Journal:  Theor Med Bioeth       Date:  1999-01

Review 2.  Microglia and the immune pathology of Alzheimer disease.

Authors:  D Giulian
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

Review 3.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

4.  Alzheimer's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

Review 5.  Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies.

Authors:  Mahyar Etminan; Sudeep Gill; Ali Samii
Journal:  BMJ       Date:  2003-07-19

6.  Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where.

Authors:  Aaron Y Lai; Joanne McLaurin
Journal:  Future Neurol       Date:  2012-03-01

Review 7.  Anti-inflammatory agents in Alzheimer's disease.

Authors:  Paul S Aisen
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

8.  Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells.

Authors:  B D Gitter; L M Cox; R E Rydel; P C May
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

Review 9.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

10.  Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain.

Authors:  B Brugg; Y L Dubreuil; G Huber; E E Wollman; N Delhaye-Bouchaud; J Mariani
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.